Annual reportSep 2026
Sep 2026 · Shareholders meeting 2 Sep - FY2025-26 annual report issued; 26th AGM on 28 September 2026 via VC/OAVM.
Source: Nse
Nidan Laboratories And Healthcare Ltd. (NIDAN)
SME CapPharma stocks · SME cap · NSE
Nidan Laboratories And Healthcare Ltd. operates in Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹12.9
-0.10 · -0.77%
Market cap ₹17.9 Cr
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result01 Jun, 08:21 pm IST
Score20 Oct, 05:22 pm IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
55Neutralfull bear SMA stack · SMA20 -4.1% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 26
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
NIDAND candles · FIT view-13.7%Latest close ₹12.90 on 2026-10-19
Bar
-0.8%
RSI
46
MACD hist
0.01
52W pos
10%
2026-10-19O ₹13.00H ₹13.40L ₹12.65C ₹12.90Vol 7,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
NIDANNifty PharmaNifty 500
- NIDAN
- -0.4%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +5.2 pp
Chart stats
19 Oct 2026- From 52W high
- -48.2%
- 52W range position
- 10%
- ATR (14)
- 4.9%
- Volume vs 20D
- 1.16x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹12.5 - ₹14
₹24.9
₹11.5 - ₹24.9
₹0.6
Latest completed session
20-session average
48.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST36
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad25
Revenue +0.6% · PAT NDF YoY
Technical
Neutral55
Price trend and sector-relative-strength timing.
Valuation
Legacy model-130.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence66
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 25/100Rev +1% YoY · margin expansion
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹12.4 Cr | +0.6% | -5.3% |
| EBITDA | ₹2.3 Cr | NDF | -9.4% |
| Operating margin | 18.5% | NDF | -84 bps |
| PAT | ₹0.1 Cr | NDF | -95.1% |
| PAT margin | 0.6% | NDF | -1034 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 10.10
- P/B
- 0.26
- EV/EBITDA
- 4.31
- Market Cap
- 17.90Cr
Profitability
- ROE
- 2.58%
- ROCE
- 5.99%
- ROA
- 1.80%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 5.00%
- EPS 5Y
- -5.00%
- Revenue 3Y
- 2.00%
- EPS 3Y
- -19.00%
Balance Sheet
- Debt/Equity
- 0.16
- Interest Coverage
- 2.47×
- Altman Z
- 2.47
- Book Value
- 50.10
Cash Flow
- FCF Yield
- 9.66%
- FCF Positive Y
- 6/5
- OCF
- 1.67 Cr
- EPS TTM
- 1.09
Shareholding
- Promoter Hold
- 57.04%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 10%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 12.4-5.3% vs prev
Net Profit
₹ CrLatest: 0.1-95.1% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 46.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~4.3% over last month) — short-term momentum negative.
- RSI(14) at 46 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 48% off 52W high · 12% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
35
RS percentile
Stage 4 Downtrend
1M return
-4.4%
3M return
-8.8%
6M return
+1.2%
1Y return
-32.5%
RS 1D
+6
RS 20D
+18
Sector rank
#1
Industry rank
#51
Stage evidence
- Price is 8.2% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -3.0%.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
weakening
Relative-strength line vs Nifty 500 (base 100)
237 observations
19 Oct 2026Value 71.28+0.27%
RS vs Nifty 50071
Valuation & peers
U-Score 36 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 36 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation20/30
Growth4/25
Quality0/20
Balance Sheet8/15
Cash Flow8/10
Piotroski
6/9 (+3)
Penalties
-7
Raw sum
36
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
36/100 · legacy band WATCHLIST
Positive drivers
- FCF yield is supportive at 9.7%.
- Cash flow contributes 8/10 to the score.
- Valuation contributes 20/30 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Fair-value margin of safety is negative at -130.6%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
10.1
PB
0.3
EV/EBITDA
4.3
ROE
2.6%
ROCE
6.0%
FCF Yield
9.7%
Debt/Equity
0.2
MoS
-130.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
36
Previous: 36
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-130.6%
Previous: -130.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
36
36
36
36
36
36
36
36
36
36
36
36
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹35.05
+63.2% MoS
Growth-justified P/E
5.1
Growth-justified Value
₹5.59
-130.6% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INVICTA
SME
Invicta Diagnostic Ltd.
Diagnostics
match 152
60
19.4
14.0%
+61%
UNDERVALUED
METROPOLIS
Micro
Metropolis Healthcare Limited
Diagnostics
match 148
39
53.4
13.6%
-562%
WATCHLIST
THYROCARE
Micro
Thyrocare Technologies Limited
Diagnostics
match 146
55
43.5
28.4%
-117%
FAIR VALUE
VIYASH
Micro
Viyash Scientific Limited
Diagnostics
match 143
45
46.6
7.4%
+15%
WATCHLIST
SAROJA
SME
Saroja Pharma Industries India Ltd.
Pharmaceuticals
match 96
48
9.8
10.1%
+77%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Nidan Laboratories And Healthcare Ltd. operates in Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
66Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 49th percentile of the scored universe and 36th percentile within Pharma. Main check: results consistency is weak at 29/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
49th percentile
overall median 67 · Pharma: 36th pctile, median 70 · SME: 60th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
89
strong · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
40
weak · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 57%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 8.8%.
- ▸6 years of positive FCF.
Trust risks
- ▸4 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 6%.
- ▸ROE is low at 2.6%.
- ▸0/4 latest quarters had positive YoY PAT growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Nidan Laboratories And Healthcare Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2026
Source: Nse
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.